Target
JAK2
4 products, 9 indications
Indications
myelofibrosis (1 products)
polycythemia vera (1 products)
steroid-refractory acute graft-versus-host disease (1 products)
corticosteroid-refractory chronic graft-versus-host disease (1 products)
mild to moderate atopic dermatitis (1 products)
Nonsegmental Vitiligo (1 products)
glioblastoma (1 products)
Ovarian cancer, primary peritoneal cancer, fallopian tube cancer (1 products)
alopecia areata (1 products)
Loading...
2 drugs
34 abstracts
Abstract
Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.Org: Memorial Sloan Kettering Cancer Center, Medical University of Silesia, Hematology Ward, S. Eugenio Hospital, The University of Texas MD Anderson Cancer Center,
Abstract
Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).Org: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Leukemia, MD Anderson Cancer Center, Houston, TX,
Abstract
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.Org: Sylvester Cancer Center, AOU Careggi, Division of Hematology and Hematologic Malignancies, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Josep Carreras Leukemia Research Institute,
Abstract
Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.Org: Washington University School of Medicine in St. Louis, The John Theurer Cancer Center at Hackensack Meridian Health, Wroclaw Medical University, Sobi Inc., Cleveland Clinic Taussig Cancer Institute,
Abstract
Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.Org: Princess Margaret Cancer Centre, University Health Network, Cleveland Clinic Taussig Cancer Institute, University of Florence, AOUC, Clinical Investigation Center,
Abstract
Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.Org: VCU Massey Comprehensive Cancer Center, Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust,
Abstract
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with polycythemia vera (PV).Org: United Lincolnshire Hospital Trust and University of Lincoln, Sunshine Coast Haematology and Oncology Clinic, Montserrat Cancer Care, The University of Sydney and Royal Prince Alfred Hospital, Royal Perth Hospital,
Abstract
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.Org: Istituto di Ematologia s. Orsola-Malpighi,
Abstract
A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.Org: Cellenkos Inc, Genève, Switzerland,
Abstract
A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).Org: Department of Pediatric Oncology,
Abstract
Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.Org: The First Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine,
Abstract
Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.Org: The Richard T. Silver, MD Myeloproliferative Neoplasms Center, Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center,
Abstract
Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States.Org: Sobi Inc., IntegraConnect, PrecisionQ, Leukemia Service,
Abstract
Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).Org: Sheba Medical Center–Tel HaShomer, Tel Aviv-Yafo, Royal Adelaide Hospital and SA Pathology,
Abstract
Outcomes of blast-phase MPN and JAK2, MPL, and CALR mutated de novo AML: A propensity score-adjusted cohort study.Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Center, University of Minnesota Medical Center,
Abstract
Association between ferritin, hemoglobin, and anemia response in jaktinib-treated patients with myelofibrosis: A post-hoc analysis of the ZGJAK006 study.Org: The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Jiangsu Provincial People’s Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalize, Shanghai Jiaotong University Medical School,
Abstract
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, The Second Affiliated Hospital of Xi'an Jiaotong University,
Abstract
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.Org: Memorial Sloan Kettering Cancer Center, Guy’s and St Thomas’ NHS Trust, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Istituto di Ematologia "Seràgnoli", Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,
Abstract
Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Cleveland Clinic Brunswick Urgent Care, Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Clonal hematopoiesis in survivors of childhood cancer.Org: New York City, St Louis, Washington University School of Medicine, ModernaTX, St. Louis,
Abstract
Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2).Org: Wake Forest University School of Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Istituto di Ematologia Seràgnoli, University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center,
Abstract
Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Alliance Statistics and Data Management Center, Vyriad,
Abstract
EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.Org: MD Anderson Cancer Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, PharmaEssentia, Rutgers University, PharmaEssentia Japan KK,
Abstract
Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Cellenkos Inc, Houston, TX, Incyte Corporation, Genève, Switzerland,
Abstract
Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University Medical Center Hamburg-Eppendorf, Princess Margaret Cancer Centre, University Health Network, University College London Hospitals NHS Foundation Trust,
Abstract
Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy, Wake Forest University School of Medicine, Winston-Salem, NC, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, Analysis Group, Boston, MA, GlaxoSmithKline USA, Collegeville, PA, GlaxoSmithKline, Philadelphia, PA, GlaxoSmithKline Pharmaceuticals, Collegeville, PA, GlaxoSmithKline, Reading, United Kingdom, Analysis Group, Inc, Boston, MA,
Abstract
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,
Abstract
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.Org: Sylvester Cancer Center, Emory University School of Medicine, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Hospital Germans Trias i Pujol, Institut Català D'Oncologia,
Abstract
PUF: A potential repressor of oncogenes.Org: East Carolina University Brody School of Medicine, East Carolina University/Vidant Cancer Center,
Abstract
Synergistic activity of JAK2 and BCL-2 inhibition against B-cell acute lymphoblastic leukemia.Org: University of Wisconsin School of Medicine and Public Health, Madison, WI,
Abstract
GLS in Philadelphia-negative and JAK2 V617F-driven myeloproliferative neoplasms (MPNs).Org: University of Chicago, Univeristy of Chicago, Policlinico San Matteo, University of Pavia, Fondazione I.R.C.C.S. Policlinico San Matteo,
Abstract
Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib.Org: Levine Cancer Institute Atrium Health, Levine Cancer Institute, Department of Hematologic Malignancies and Blood Disorders, Yale School of Medicine, Yale University,
Drug
RuxolitinibDrug
LITFULO